Oxidien Pharmaceuticals Announce Additions to New Strategic Advisory Board

UF Innovate | The Hub resident client Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, announced two additions to its newly organized Strategic Advisory Board (SAB). Allen R. Nissenson, MD, and John G. Cooper will be working closely with the CEO and management team to provide strategic advice in the critical areas ranging from clinical to corporate development.

“I am excited to announce the creation of our strategic advisory board and to invite Allen Nissenson and John Cooper as inaugural members,” said Helena Cowley, chief executive officer of Oxidien. “I look forward to working with both John and Allen to continue to build value and position us well for the future.”

Learn more about Oxidien Pharmaceuticals Announce Additions to New Strategic Advisory Board.